Application of clot‐fibrinolysis waveform analysis to assessment of in vitro effects of direct oral anticoagulants on fibrinolysis. (20th February 2020)

• Record Type: Journal Article
• Authors: Oka, Shusaku; Wakui, Masatoshi; Fujimori, Yuta; Kuroda, Yuko; Nakamura, Shoko; Kondo, Yoshino; Nakagawa, Terumichi; Katagiri, Hisako; Murata, Mitsuru
• Is Part Of: International journal of laboratory hematology. Volume 42:Number 3(2020:Jun.)
• Page Start: 292
• Page End: 298
• Publication Date: 2020-02-20
• Subjects: activated partial thromboplastin time -- clot‐fibrinolysis waveform analysis -- direct oral anticoagulants -- maximum fibrinolysis velocity -- tissue plasminogen activator; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; 616.15005
• DOI: 10.1111/ijlh.13168
• Languages: English
• ISSNs: 1751-5521

Abstract

Abstract: Introduction: Acceleration of fibrinolysis by direct oral anticoagulants (DOACs) has been reported by several groups, suggesting contribution of not only anticoagulant but also fibrinolytic effects to the therapeutic efficacy. The present study aims to evaluate the usability of clot‐fibrinolysis waveform analysis (CFWA) for assessment of in vitro effects of DOACs on fibrinolysis. Methods: The experimental conditions were optimized according to how t‐PA concentrations and a time length after t‐PA adjustment affect parameters of CFWA. Addition of the activated partial thromboplastin time (APTT) reagent followed by that of calcium and t‐PA was done to obtain clotting and fibrinolytic reaction curves which were mathematically differentiated for CFWA (APTT‐CFWA). The positive and negative modes of waveforms were defined as the direction toward fibrin generation and that toward fibrin degradation, respectively. The maximum positive and negative values (Maxp 1 and Maxn 1) correspond to the maximum coagulation velocity and the maximum fibrinolysis velocity, respectively. Plasma spiked with each of DOACs (rivaroxaban, apixaban, edoxaban, and dabigatran) was subjected to APTT‐CFWA. Results: Optimization of t‐PA use was based on Maxn 1. Roughly biphasic effects of rivaroxaban and dabigatran but not apixaban or edoxaban on fibrinolysis were observed through Maxn 1 and the fibrinolysis peak time, which was defined as a time length from the time when Maxp 1 (Maxp 1 time) to the time when Maxn 1 appears (Maxn 1 time). Conclusion: The results suggest the usability of CFWA for assessment of DOAC effects and provide insights into relevance of anticoagulation to therapeutic efficacy and bleeding risk from the perspective of fibrinolysis.